Piha-Paul, Sarina A.

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 3,788

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,552

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 780

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine

RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions

Cited by 445

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 424

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 219

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 105

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

Marabelle, A., Fakih, M. G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 104

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

Doi, T., Patel, M., Falchook, G. S., Koyama, T., Friedman, C. F., Piha-Paul, S., Gutierrez, M. E., Abdul-Karim, R., Awad, M., Adkins, D. R., et al. (2022) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 44

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

Tsimberidou, A.-M., Vo, H. H., Subbiah, V., Janku, F., Piha-Paul, S., Yilmaz, B., Gong, J., Naqvi, M. F., Tu, S.-M., Campbell, M., et al. (2021) · The Oncologist

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 43

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 34

690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

Patel, M. R., Doi, T., Koyama, T., Falchook, G. S., Friedman, C. F., Piha-Paul, S. A., Gutierrez, M., Awad, M. M., Mattour, A. H., Satoh, T., et al. (2023) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 33

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 30

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Mita, M., Fu, S., Piha-Paul, S. A., Janku, F., Mita, A., Natale, R., Guo, W., Zhao, C., Kurzrock, R., & Naing, A. (2017) · Investigational New Drugs

Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 26

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population

Wheler, J., Falchook, G., Tsimberidou, A. M., Hong, D., Naing, A., Piha-Paul, S., Chen, S. S., Heymach, J., Fu, S., Stephen, B., et al. (2013) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 17